Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by Madison Asset Management LLC

Madison Asset Management LLC boosted its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 39.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 9,683 shares of the company's stock after buying an additional 2,737 shares during the quarter. Madison Asset Management LLC's holdings in Medpace were worth $2,950,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Proficio Capital Partners LLC grew its stake in shares of Medpace by 4.1% during the 4th quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock worth $243,000 after acquiring an additional 29 shares during the period. HighTower Advisors LLC grew its stake in shares of Medpace by 4.7% during the 4th quarter. HighTower Advisors LLC now owns 3,140 shares of the company's stock worth $1,043,000 after acquiring an additional 142 shares during the period. Corient Private Wealth LLC grew its stake in shares of Medpace by 86.1% during the 4th quarter. Corient Private Wealth LLC now owns 2,380 shares of the company's stock worth $791,000 after acquiring an additional 1,101 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of Medpace during the 4th quarter worth $2,093,000. Finally, LPL Financial LLC grew its stake in shares of Medpace by 5.3% during the 4th quarter. LPL Financial LLC now owns 17,960 shares of the company's stock worth $6,010,000 after acquiring an additional 909 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

MEDP has been the subject of several analyst reports. Robert W. Baird raised their target price on Medpace from $313.00 to $490.00 and gave the stock a "neutral" rating in a research note on Wednesday. TD Cowen reaffirmed a "sell" rating and issued a $366.00 price target (up previously from $283.00) on shares of Medpace in a report on Wednesday. Mizuho raised their price target on Medpace from $328.00 to $510.00 and gave the company an "outperform" rating in a report on Friday. Truist Financial raised their price target on Medpace from $298.00 to $436.00 and gave the company a "hold" rating in a report on Wednesday. Finally, Barclays raised their price target on Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a report on Wednesday. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $411.10.

Medpace Trading Down 1.8%

MEDP stock traded down $8.19 during trading on Friday, reaching $447.49. The stock had a trading volume of 763,602 shares, compared to its average volume of 461,353. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $501.30. The stock's 50 day moving average is $316.82 and its two-hundred day moving average is $320.36. The firm has a market cap of $12.86 billion, a PE ratio of 33.27, a PEG ratio of 7.96 and a beta of 1.47.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating the consensus estimate of $3.00 by $0.10. The business had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%. The business's revenue was up 14.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.75 earnings per share. On average, research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.